Cargando…
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities
Melanoma, a cancer of the skin, arises from transformed melanocytes. Melanoma has the highest mutational burden of any cancer partially attributed to UV induced DNA damage. Localized melanoma is “curable” by surgical resection and is followed by radiation therapy to eliminate any remaining cancer ce...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891057/ https://www.ncbi.nlm.nih.gov/pubmed/33614507 http://dx.doi.org/10.3389/fonc.2020.626129 |
_version_ | 1783652625117347840 |
---|---|
author | Eddy, Kevinn Shah, Raj Chen, Suzie |
author_facet | Eddy, Kevinn Shah, Raj Chen, Suzie |
author_sort | Eddy, Kevinn |
collection | PubMed |
description | Melanoma, a cancer of the skin, arises from transformed melanocytes. Melanoma has the highest mutational burden of any cancer partially attributed to UV induced DNA damage. Localized melanoma is “curable” by surgical resection and is followed by radiation therapy to eliminate any remaining cancer cells. Targeted therapies against components of the MAPK signaling cascade and immunotherapies which block immune checkpoints have shown remarkable clinical responses, however with the onset of resistance in most patients, and, disease relapse, these patients eventually become refractory to treatments. Although great advances have been made in our understanding of the metastatic process in cancers including melanoma, therapy failure suggests that much remains to be learned and understood about the multi-step process of tumor metastasis. In this review we provide an overview of melanocytic transformation into malignant melanoma and key molecular events that occur during this evolution. A better understanding of the complex processes entailing cancer cell dissemination will improve the mechanistic driven design of therapies that target specific steps involved in cancer metastasis to improve clinical response rates and overall survival in all cancer patients. |
format | Online Article Text |
id | pubmed-7891057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78910572021-02-19 Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities Eddy, Kevinn Shah, Raj Chen, Suzie Front Oncol Oncology Melanoma, a cancer of the skin, arises from transformed melanocytes. Melanoma has the highest mutational burden of any cancer partially attributed to UV induced DNA damage. Localized melanoma is “curable” by surgical resection and is followed by radiation therapy to eliminate any remaining cancer cells. Targeted therapies against components of the MAPK signaling cascade and immunotherapies which block immune checkpoints have shown remarkable clinical responses, however with the onset of resistance in most patients, and, disease relapse, these patients eventually become refractory to treatments. Although great advances have been made in our understanding of the metastatic process in cancers including melanoma, therapy failure suggests that much remains to be learned and understood about the multi-step process of tumor metastasis. In this review we provide an overview of melanocytic transformation into malignant melanoma and key molecular events that occur during this evolution. A better understanding of the complex processes entailing cancer cell dissemination will improve the mechanistic driven design of therapies that target specific steps involved in cancer metastasis to improve clinical response rates and overall survival in all cancer patients. Frontiers Media S.A. 2021-02-04 /pmc/articles/PMC7891057/ /pubmed/33614507 http://dx.doi.org/10.3389/fonc.2020.626129 Text en Copyright © 2021 Eddy, Shah and Chen http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Eddy, Kevinn Shah, Raj Chen, Suzie Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities |
title | Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities |
title_full | Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities |
title_fullStr | Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities |
title_full_unstemmed | Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities |
title_short | Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities |
title_sort | decoding melanoma development and progression: identification of therapeutic vulnerabilities |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891057/ https://www.ncbi.nlm.nih.gov/pubmed/33614507 http://dx.doi.org/10.3389/fonc.2020.626129 |
work_keys_str_mv | AT eddykevinn decodingmelanomadevelopmentandprogressionidentificationoftherapeuticvulnerabilities AT shahraj decodingmelanomadevelopmentandprogressionidentificationoftherapeuticvulnerabilities AT chensuzie decodingmelanomadevelopmentandprogressionidentificationoftherapeuticvulnerabilities |